|
Real-time Estimate
Cboe BZX
20:59:01 23/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 26.28 USD | -2.21% |
|
+6.41% | +10.07% |
| 09-16 | TD Cowen Initiates Arcus Biosciences at Buy | MT |
| 09-15 | Arcus Biosciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 12:20 PM |
Company Valuation: Arcus Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,843 | 1,497 | 1,430 | 1,363 | 2,948 | 3,421 | - | - |
| Change | - | -47.33% | -4.52% | -4.7% | 116.38% | 16.04% | - | - |
| Enterprise Value (EV) 1 | 2,344 | 488.4 | 670.7 | 384.6 | 2,066 | 2,981 | 3,319 | 3,116 |
| Change | - | -79.16% | 37.34% | -42.66% | 437.29% | 44.25% | 11.36% | -6.12% |
| P/E | 57x | -5.57x | -4.6x | -4.74x | -7.24x | -7.52x | -7.44x | -8.56x |
| PBR | - | 2.29x | 3.12x | 2.83x | 4.73x | 12.4x | -37.3x | 9.36x |
| PEG | - | 0x | -0.4x | 0.2x | -1.52x | -0.87x | -7.24x | 0.7x |
| Capitalization / Revenue | 7.43x | 13.4x | 12.2x | 5.28x | 11.9x | 43.9x | 67.1x | 20.6x |
| EV / Revenue | 6.12x | 4.36x | 5.73x | 1.49x | 8.37x | 38.3x | 65.1x | 18.8x |
| EV / EBITDA | 40.3x | -1.78x | -2.02x | -1.28x | -5.5x | -6.72x | -6.77x | -11.8x |
| EV / EBIT | 43.2x | -1.74x | -1.97x | -1.17x | -5.35x | -6.26x | -6.74x | -6.84x |
| EV / FCF | -8.3x | 1.13x | - | -2.19x | -4.27x | -9.59x | -8.67x | -10.2x |
| FCF Yield | -12% | 88.5% | - | -45.8% | -23.4% | -10.4% | -11.5% | -9.83% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.71 | -3.71 | -4.15 | -3.14 | -3.29 | -3.575 | -3.612 | -3.14 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 382.9 | 112 | 117 | 258 | 247 | 77.89 | 50.98 | 165.9 |
| EBITDA 1 | 58.09 | -274 | -332 | -300 | -376 | -443.4 | -490.2 | -264.1 |
| EBIT 1 | 54.25 | -280 | -340 | -330 | -386 | -475.9 | -492.8 | -455.7 |
| Net income 1 | 52.83 | -267 | -307 | -283 | -353 | -450.9 | -453.9 | -398.5 |
| Net Debt 1 | -499.3 | -1,009 | -759 | -978 | -882 | -440.6 | -102.2 | -305.4 |
| Reference price 2 | 40.47 | 20.68 | 19.10 | 14.89 | 23.83 | 26.87 | 26.87 | 26.87 |
| Nbr of stocks (in thousands) | 70,249 | 72,408 | 74,856 | 91,512 | 123,729 | 127,333 | - | - |
| Announcement Date | 2/23/22 A | 2/28/23 A | 2/21/24 A | 2/25/25 A | 2/25/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.52x | 38.27x | -6.72x | -.--% | 3.42B | |
| 32.89x | 5.91x | 17.69x | 0.99% | 47.86B | |
| 34.78x | 3.35x | 14.44x | -.--% | 44.46B | |
| 48.22x | 5.6x | 30.63x | -.--% | 41.85B | |
| -19.82x | 211.04x | -21.38x | -.--% | 41.34B | |
| 27.01x | 7.79x | 20.05x | 0.42% | 30.04B | |
| 35.84x | 5.89x | 26.75x | -.--% | 17.59B | |
| 26.32x | 2.25x | 9.76x | 1.02% | 15.69B | |
| -55.43x | 9.1x | 222.2x | -.--% | 13.93B | |
| Average | 13.59x | 32.13x | 34.82x | 0.27% | 28.46B | |
| Weighted average by Cap. | 20.99x | 39.11x | 24.14x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RCUS Stock
- Valuation Arcus Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
